Davis's Drug Guide
niraparib
General
High Alert Medication: This medication bears a heightened risk of causing significant patient harm when it is used in error.
Genetic Implications:
Pronunciation:
nye-rap-a-rib
To hear audio pronunciation of this topic, purchase a subscription or log in.Trade Name(s)
- Zejula
Ther. Class.
Pharm. Class.
enzyme inhibitors
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Niraparib." Davis's Drug Guide, 19th ed., F.A. Davis Company, 2025. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110440/all/niraparib.
Vallerand AHA, Sanoski CAC, . Niraparib. Davis's Drug Guide. F.A. Davis Company; 2025. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110440/all/niraparib. Accessed February 22, 2025.
Vallerand, A. H., Sanoski, C. A., & , (2025). Niraparib. In Davis's Drug Guide (19th ed.). F.A. Davis Company. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110440/all/niraparib
Vallerand AHA, Sanoski CAC, . Niraparib [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2025. [cited 2025 February 22]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110440/all/niraparib.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - niraparib
ID - 110440
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - ,,
BT - Davis's Drug Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110440/all/niraparib
PB - F.A. Davis Company
ET - 19
DB - Pediatrics Central
DP - Unbound Medicine
ER -
